NasdaqCM:EKSO

Stock Analysis Report

Executive Summary

Ekso Bionics Holdings, Inc. designs, develops, and sells exoskeletons for use in the healthcare, industrial, and military markets in North America, Europe, the Middle East, and Africa.

Snowflake

Fundamentals

Mediocre balance sheet with limited growth.

Risks

  • Ekso Bionics Holdings has significant price volatility in the past 3 months.
  • Ekso Bionics Holdings is covered by less than 3 analysts.

Similar Companies

Share Price & News

How has Ekso Bionics Holdings's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-4.1%

EKSO

1.2%

US Medical Equipment

-0.6%

US Market


1 Year Return

-76.9%

EKSO

9.7%

US Medical Equipment

0.7%

US Market

EKSO underperformed the Medical Equipment industry which returned 9.9% over the past year.

EKSO underperformed the Market in United States of America which returned 0.7% over the past year.


Share holder returns

EKSOIndustryMarket
7 Day-4.1%1.2%-0.6%
30 Day-29.3%3.5%4.9%
90 Day-57.7%3.2%1.7%
1 Year-76.9%-76.9%10.6%9.7%3.0%0.7%
3 Year-85.1%-85.1%70.6%65.4%44.8%35.4%
5 Year-90.7%-90.7%139.4%112.2%62.0%44.3%

Price Volatility Vs. Market

How volatile is Ekso Bionics Holdings's share price compared to the market and industry in the last 5 years?


Simply Wall St News

2 weeks ago | Simply Wall St

What Kind Of Shareholders Own Ekso Bionics Holdings, Inc. (NASDAQ:EKSO)?

Valuation

Is Ekso Bionics Holdings undervalued based on future cash flows and its price relative to the stock market?

7.45x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Unable to calculate intrinsic value for Ekso Bionics Holdings to establish if it is available at moderate discount.

Unable to calculate intrinsic value for Ekso Bionics Holdings to establish if it is available at substantial discount.


Price Based on Earnings

Ekso Bionics Holdings is loss making, we can't compare its value to the US Medical Equipment industry average.

Ekso Bionics Holdings is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Ekso Bionics Holdings, we can't assess if its growth is good value.


Price Based on Value of Assets

Ekso Bionics Holdings is overvalued based on assets compared to the US Medical Equipment industry average.


Next Steps

Future Growth

How is Ekso Bionics Holdings expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

8.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Ekso Bionics Holdings's revenue is expected to grow significantly at over 20% yearly.

Ekso Bionics Holdings is not considered high growth as it is expected to be loss making for the next 1-3 years.

Ekso Bionics Holdings's revenue growth is expected to exceed the United States of America market average.

Unable to compare Ekso Bionics Holdings's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.

Unable to compare Ekso Bionics Holdings's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if Ekso Bionics Holdings will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has Ekso Bionics Holdings performed over the past 5 years?

-9.3%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Ekso Bionics Holdings does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare Ekso Bionics Holdings's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Ekso Bionics Holdings's 1-year growth to the US Medical Equipment industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Ekso Bionics Holdings has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if Ekso Bionics Holdings has efficiently used its assets last year compared to the US Medical Equipment industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Ekso Bionics Holdings improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Ekso Bionics Holdings's financial position?


Financial Position Analysis

Ekso Bionics Holdings is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Ekso Bionics Holdings's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Ekso Bionics Holdings's level of debt (71.6%) compared to net worth is high (greater than 40%).

Ekso Bionics Holdings had negative shareholder equity 5 years ago, it is now positive therefore their debt level has improved.


Balance Sheet

High level of physical assets or inventory.

Debt is covered by short term assets, assets are 5.7x debt.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Ekso Bionics Holdings has less than a year of cash runway based on current free cash flow.

Ekso Bionics Holdings has less than a year of cash runway if free cash flow continues to reduce at historical rates of -8.1% each year.


Next Steps

Dividend

What is Ekso Bionics Holdings's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Ekso Bionics Holdings's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Ekso Bionics Holdings's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Ekso Bionics Holdings has not reported any payouts.

Unable to verify if Ekso Bionics Holdings's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Ekso Bionics Holdings has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Ekso Bionics Holdings's salary, the management and board of directors tenure and is there insider trading?

1.3yrs

Average management tenure


CEO

Jack Peurach (53yo)

1.5yrs

Tenure

US$4,367,123

Compensation

Mr. Jack Peurach has been President and Chief Executive Officer at Ekso Bionics Holdings, Inc. since March 9, 2018. Mr. Peurach served as an Executive Vice President of Products at SunPower Corporation sin ...


CEO Compensation Analysis

Jack's remuneration is higher than average for companies of similar size in United States of America.

Jack's compensation has increased whilst company is loss making.


Management Age and Tenure

1.3yrs

Average Tenure

55yo

Average Age

The average tenure for the Ekso Bionics Holdings management team is less than 2 years, this suggests a new team.


Board Age and Tenure

5.7yrs

Average Tenure

62yo

Average Age

The tenure for the Ekso Bionics Holdings board of directors is about average.


Insider Trading

No 3 month open market individual insider trading information.


Recent Insider Transactions

SellUS$43,06919 Jun 19
Jack Peurach
EntityIndividual
Role
Chief Executive Officer
President
Shares31,437
Max PriceUS$1.37
SellUS$12,35319 Jun 19
Jason Jones
EntityIndividual
Shares9,430
Max PriceUS$1.31
SellUS$14,10019 Jun 19
John Glenn
EntityIndividual
Role
Chief Financial Officer
CFO & Secretary
Shares10,292
Max PriceUS$1.37

Ownership Breakdown


Management Team

  • Jack Glenn (57yo)

    CFO & Secretary

    • Tenure: 1.1yrs
    • Compensation: US$1.04m
  • Steven Sherman (73yo)

    Executive Chairman

    • Tenure: 5.7yrs
    • Compensation: US$1.53m
  • Jack Peurach (53yo)

    President

    • Tenure: 1.5yrs
    • Compensation: US$4.37m
  • Bill Shaw (45yo)

    Chief Commercial Officer

    • Tenure: 0.4yrs
  • Matthias Stief

    Managing Director of Ekso Bionics Europe GmbH

    • Tenure: 2.8yrs
  • Foon Lim Chwee

    President of APAC

    • Tenure: 1.7yrs

Board Members

  • Stanley Stern (62yo)

    Independent Director

    • Tenure: 4.8yrs
    • Compensation: US$101.77k
  • Tom Schreck (61yo)

    Director

    • Tenure: 0.8yrs
    • Compensation: US$46.44k
  • Steven Sherman (73yo)

    Executive Chairman

    • Tenure: 5.7yrs
    • Compensation: US$1.53m
  • Marilyn Hamilton (70yo)

    Independent Director

    • Tenure: 5.7yrs
    • Compensation: US$98.03k
  • Hans Keirstead

    Member of Advisory Council

    • Tenure: 0yrs
  • Jack Peurach (53yo)

    President

    • Tenure: 1.5yrs
    • Compensation: US$4.37m
  • Nancy Byl

    Member of Advisory Council

    • Tenure: 0yrs
  • Tom Kelley

    Member of Advisory Council

    • Tenure: 0yrs
  • Kel Bergmann

    Member of Advisory Council

    • Tenure: 0yrs
  • Graham Creasey

    Member of Advisory Council

    • Tenure: 0yrs

Company Information

Ekso Bionics Holdings, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Ekso Bionics Holdings, Inc.
  • Ticker: EKSO
  • Exchange: NasdaqCM
  • Founded: 2005
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$40.284m
  • Shares outstanding: 74.92m
  • Website: https://www.eksobionics.com

Number of Employees


Location

  • Ekso Bionics Holdings, Inc.
  • 1414 Harbour Way South
  • Suite 1201
  • Richmond
  • California
  • 94804
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
EKSONasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDJan 2014
230DB (Deutsche Boerse AG)YesCommon StockDEEURJan 2014
0IFRLSE (London Stock Exchange)YesCommon StockGBUSDJan 2014

Biography

Ekso Bionics Holdings, Inc. designs, develops, and sells exoskeletons for use in the healthcare, industrial, and military markets in North America, Europe, the Middle East, and Africa. The company operates ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/23 00:27
End of Day Share Price2019/09/20 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.